Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
993 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05463952 | A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC) | active not recruiting | Phase 1 | 6 | PfizerINDUSTRY | 1 | Nov 13, 2024 | clinicaltrials |
| NCT04060862 | A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer(IPATunity150) | terminated | Phase 1 | 20 | Hoffmann-La RocheINDUSTRY |
| 8 |
| Nov 8, 2024 |
| clinicaltrials |
| NCT02181660 | Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 24 | Astellas Pharma IncINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05567887 | A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies | completed | Phase 1 | 7 | PfizerINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03565445 | A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 190 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Nov 1, 2024 | clinicaltrials |
| NCT04094506 | Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 9 | Astellas Pharma IncINDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT02038673 | An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors | completed | Phase 1 | 86 | Astellas Pharma IncINDUSTRY | 4 | Oct 31, 2024 | clinicaltrials |
| NCT02980341 | Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 182 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Oct 30, 2024 | clinicaltrials |
| NCT01436656 | A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma | completed | Phase 1 | 107 | PfizerINDUSTRY | 7 | Oct 28, 2024 | clinicaltrials |
| NCT02325739 | FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | completed | Phase 1 / Phase 2 | 172 | Novartis PharmaceuticalsINDUSTRY | 11 | Oct 21, 2024 | clinicaltrials |
| NCT03070990 | A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma | completed | Phase 1 | 19 | Astellas Pharma IncINDUSTRY | 1 | Oct 18, 2024 | clinicaltrials |
| NCT03541369 | Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia(20170528) | terminated | Phase 1 | 64 | AmgenINDUSTRY | 6 | Oct 10, 2024 | clinicaltrials |
| NCT04138823 | A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours) | completed | Phase 1 | 12 | Boehringer IngelheimINDUSTRY | 1 | Oct 9, 2024 | clinicaltrials |
| NCT04521621 | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | terminated | Phase 1 / Phase 2 | 76 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Oct 1, 2024 | clinicaltrials |
| NCT04798586 | MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma | completed | Phase 1 | 4 | PfizerINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05298592 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | completed | Phase 1 | 77 | Bristol-Myers SquibbINDUSTRY | 6 | Sep 26, 2024 | clinicaltrials |
| NCT02509039 | A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 1 | 15 | CelgeneINDUSTRY | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03453164 | Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT) | completed | Phase 1 / Phase 2 | 41 | Fukushima Medical UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04742556 | A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) | completed | Phase 1 | 15 | Boehringer IngelheimINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06540261 | The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer | active not recruiting | Phase 1 | 65 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05022927 | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma | active not recruiting | Phase 1 | 179 | Chugai PharmaceuticalINDUSTRY | 2 | Sep 5, 2024 | clinicaltrials |
| NCT03343054 | A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 28 | PfizerINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05251727 | Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients | terminated | Phase 1 | 77 | Veloxis PharmaceuticalsINDUSTRY | 2 | Aug 19, 2024 | clinicaltrials |
| NCT01970865 | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | completed | Phase 1 / Phase 2 | 364 | PfizerINDUSTRY | 14 | Aug 12, 2024 | clinicaltrials |
| NCT06547385 | Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer | active not recruiting | Phase 1 | 40 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06542731 | An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 42 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05469919 | An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies | completed | Phase 1 | 12 | AstraZenecaINDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02443324 | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer | completed | Phase 1 | 175 | Eli Lilly and CompanyINDUSTRY | 6 | Jul 31, 2024 | clinicaltrials |
| NCT04454476 | Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor | unknown | Phase 1 | 15 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT02554812 | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | terminated | Phase 1 / Phase 2 | 409 | PfizerINDUSTRY | 8 | Jul 30, 2024 | clinicaltrials |
| NCT04402008 | Study of Poziotinib in Japanese Patients With NSCLC | terminated | Phase 1 / Phase 2 | 42 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03301896 | Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | terminated | Phase 1 | 45 | Novartis PharmaceuticalsINDUSTRY | 7 | Jun 20, 2024 | clinicaltrials |
| NCT03418922 | A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma | completed | Phase 1 | 30 | Eisai Co., Ltd.INDUSTRY | 1 | Jun 20, 2024 | clinicaltrials |
| NCT04074330 | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 38 | TakedaINDUSTRY | 9 | Jun 14, 2024 | clinicaltrials |
| NCT02517398 | MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors | completed | Phase 1 | 600 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 12 | May 3, 2024 | clinicaltrials |
| NCT04403308 | ONO-7913 Phase I Study (ONO-7913) | completed | Phase 1 | 7 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05064618 | Investigator-initiated Clinical Trial of MIKE-1(MIKE-1) | unknown | Phase 1 / Phase 2 | 55 | Nagoya UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT02812706 | Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients(Islands) | completed | Phase 1 / Phase 2 | 36 | SanofiINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT02081378 | A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL | completed | Phase 1 | 326 | Novartis PharmaceuticalsINDUSTRY | 10 | Mar 18, 2024 | clinicaltrials |
| NCT04551950 | Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046) | completed | Phase 1 | 25 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Mar 8, 2024 | clinicaltrials |
| NCT03604445 | This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) | terminated | Phase 1 | 37 | Boehringer IngelheimINDUSTRY | 4 | Mar 4, 2024 | clinicaltrials |
| NCT04276415 | DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST) | terminated | Phase 1 | 34 | Daiichi SankyoINDUSTRY | 2 | Feb 15, 2024 | clinicaltrials |
| NCT03639194 | A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 1 | 132 | AbbVieINDUSTRY | 4 | Feb 9, 2024 | clinicaltrials |
| NCT04176016 | Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma | terminated | Phase 1 | 12 | OncoTherapy Science, Inc.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05240612 | A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM) | completed | Phase 1 | 15 | Tanabe Pharma CorporationINDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT02564900 | Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors | completed | Phase 1 | 292 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Jan 22, 2024 | clinicaltrials |
| NCT02829723 | A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 192 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 18, 2024 | clinicaltrials |
| NCT03006926 | A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | completed | Phase 1 | 104 | Eisai Co., Ltd.INDUSTRY | 7 | Dec 13, 2023 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials